Nanochap raises ¥500M as three blind patients test its retinal implant
Gaorong led the round as Jiawei Yang's Hangzhou company reports three implanted patients and ¥1B raised to date.
By RuntimeWire Staff · Published
Primary source: Cyzone
Why it matters
Visual restoration is the BCI segment with the clearest patient need and the hardest evidence bar. Nanochap now has ¥1B in cumulative funding, a 320-channel retinal implant in GCP clinical testing and a 1,280-channel cortical program behind it, placing a Chinese company with its own chips, electrodes and packaging in the same race as Science Corporation's CE-marked PRIMA and Neuralink's Blindsight. The open question is evidence: three company-reported patient cases are a start, and published cohort data are what investors and regulators will eventually price.
Hangzhou-based Nanochap Electronics, co-founded by Jiawei Yang and Nhan Tran, has raised a ¥500 million C+ round to push its visual brain-computer interfaces through clinical testing. Gaorong Ventures led the round, with PICC Equity, Monolith Capital, C&D Emerging, Orient Jiafu, Danhe Capital and Hangzhou Industrial Investment joining, while Legend Capital and other existing investors increased their commitments, according to Cyzone.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.